ZFN Technology Advances Biopharmaceutical Manufacturing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

ZFN Technology Advances Biopharmaceutical Manufacturing
Applications of ZFN technology in biopharmaceutical cell-line engineering.

Pharmaceutical Technology
Volume 37, Issue 5, pp. 20-23

Genome editing has played a prominent role in the development of Chinese Hamster Ovary (CHO) cells for biopharmaceutical processes. The DUKXB11 cell line was created in 1980 by introducing mutations in the dihydrofolate reductase (DHFR) locus. Although the engineered cells were not intended for stable recombinant protein production, the DHFR modification provided a potent metabolic selection marker, and the cell line was quickly used to create stably transfected pools.

As knowledge of the CHO genome has increased, many more potential genomic targets have been identified. Genome editing is now routinely used as a tool to aid biopharmaceutical production. When the DUKXB11 cell line was developed in 1980, the only available genomic modification techniques were exposure to chemical mutagens or radiation. Massive screening and selection methods were therefore required to identify cells with the desired genotype. Mutations in the DUKXB11 cell line were introduced by exposing CHO cells to ethyl methanesulfonate or gamma radiation. The cells went through many rounds of selection using [3H] deoxyuridine to isolate clones that contained the desired genotype. These mutagenesis techniques could introduce undesired random mutations throughout the genome and require massive selection strategies to identify clones with the desired genotype. Today, there are several technologies that enable the user to edit the genome more precisely. One of these technologies is the use of zinc finger nucleases (ZFNs).

Zinc finger nucleases

A zinc finger motif is a natural lyoccurring small protein made up of approximately 30 amino acids, stabilized by at least one zinc ion. Each zinc finger motif binds to a specific set of three nucleotide bases. When several of these zinc finger motifs are connected, they target a precise genomic sequence. A ZFN is formed when a FokI endonuclease is fused to these zinc finger motifs.

ZFNs are designed in pairs that bind to adjacent sequences. When the pair of ZFNs binds to the adjacent sequences, their FokI endonucleases heterodimerize, cutting the DNA at that location. In other words, ZFNs target a specific sequence of DNA and create a double-stranded break (DSB) at that precise location.

Once the DSB has been created, the user can then create specific deletions or insertions at that location, using the natural repair mechanisms of the cell. The precision and accuracy of ZFNs reduce the screening and selection processes needed to identify cells with the desired genotype, reducing timelines.

Other technologies, such as meganucleases or TALENS (i.e., transcription activator-like effector nucleases), can also create targeted changes in a genome. Mega-nucleases (from Precision Biosciences and Cellectis) are restriction enzymes found in single-celled organisms that recognize a large (>20bp) DNA sequence. The disadvantage of this technology is that the protein-engineering process takes several months and cutting efficiencies can be low. TALENS consist of a TALE DNA binding domain that gives sequence-specific recognition, fused to the catalytic domain of an endonuclease. Much like ZFNs, TALENS bind to a specific sequence of DNA and create a DSB. There is, however, a lack of precedence for using them clinically and no clear path to commercial use. In contrast, ZFNs have been used in gene therapy trials. Sigma-Aldrich holds an exclusive license for the ZFN technology through Sangamo Biosciences.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here